Cargando…

Serum Pro‐N‐Cadherin Is a Marker of Subclinical Heart Failure in the General Population

BACKGROUND: We recently reported aberrant processing and localization of the precursor PNC (pro‐N‐cadherin) protein in failing heart tissues and detected elevated PNC products in the plasma of patients with heart failure. We hypothesize that PNC mislocalization and subsequent circulation is an early...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrell, Paul Durham, Oristian, Kristianne Michelle, Puranam, Ishaan, Pizzo, Salvatore Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111553/
https://www.ncbi.nlm.nih.gov/pubmed/36892069
http://dx.doi.org/10.1161/JAHA.122.028234
_version_ 1785027480663359488
author Ferrell, Paul Durham
Oristian, Kristianne Michelle
Puranam, Ishaan
Pizzo, Salvatore Vincent
author_facet Ferrell, Paul Durham
Oristian, Kristianne Michelle
Puranam, Ishaan
Pizzo, Salvatore Vincent
author_sort Ferrell, Paul Durham
collection PubMed
description BACKGROUND: We recently reported aberrant processing and localization of the precursor PNC (pro‐N‐cadherin) protein in failing heart tissues and detected elevated PNC products in the plasma of patients with heart failure. We hypothesize that PNC mislocalization and subsequent circulation is an early event in the pathogenesis of heart failure, and therefore circulating PNC is an early biomarker of heart failure. METHODS AND RESULTS: In collaboration with the Duke University Clinical and Translational Science Institute's MURDOCK (Measurement to Understand Reclassification of Disease of Cabarrus and Kannapolis) study, we queried enrolled individuals and sampled 2 matched cohorts: a cohort of individuals with no known heart failure at the time of serum collection and no heart failure development in the following 13 years (n=289, cohort A) and a matching cohort of enrolled individuals who had no known heart failure at the time of serum collection but subsequently developed heart failure within the following 13 years (n=307, cohort B). Serum PNC and NT‐proBNP (N‐terminal pro B‐type natriuretic peptide) concentrations in each population were quantified by ELISA. We detected no significant difference in NT‐proBNP rule‐in or rule‐out statistics between the 2 cohorts at baseline. In participants who developed heart failure, serum PNC is significantly elevated relative to those who did not report development of heart failure (P<0.0001). Receiver operating characteristic analyses of PNC demonstrate diagnostic value for subclinical heart failure. Additionally, PNC has diagnostic potential when comparing participants with no reported heart failure risk factors from cohort A to at‐risk participants from cohort B over the 13‐year follow‐up. Participants whose PNC levels measure >6 ng/mL have a 41% increased risk of all‐cause mortality independent of age, body mass index, sex, NT‐proBNP, blood pressure, previous heart attack, and coronary artery disease (P=0.044, n=596). CONCLUSIONS: These data suggest that PNC is an early marker of heart failure and has the potential to identify patients who would benefit from early therapeutic intervention.
format Online
Article
Text
id pubmed-10111553
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101115532023-04-19 Serum Pro‐N‐Cadherin Is a Marker of Subclinical Heart Failure in the General Population Ferrell, Paul Durham Oristian, Kristianne Michelle Puranam, Ishaan Pizzo, Salvatore Vincent J Am Heart Assoc Original Research BACKGROUND: We recently reported aberrant processing and localization of the precursor PNC (pro‐N‐cadherin) protein in failing heart tissues and detected elevated PNC products in the plasma of patients with heart failure. We hypothesize that PNC mislocalization and subsequent circulation is an early event in the pathogenesis of heart failure, and therefore circulating PNC is an early biomarker of heart failure. METHODS AND RESULTS: In collaboration with the Duke University Clinical and Translational Science Institute's MURDOCK (Measurement to Understand Reclassification of Disease of Cabarrus and Kannapolis) study, we queried enrolled individuals and sampled 2 matched cohorts: a cohort of individuals with no known heart failure at the time of serum collection and no heart failure development in the following 13 years (n=289, cohort A) and a matching cohort of enrolled individuals who had no known heart failure at the time of serum collection but subsequently developed heart failure within the following 13 years (n=307, cohort B). Serum PNC and NT‐proBNP (N‐terminal pro B‐type natriuretic peptide) concentrations in each population were quantified by ELISA. We detected no significant difference in NT‐proBNP rule‐in or rule‐out statistics between the 2 cohorts at baseline. In participants who developed heart failure, serum PNC is significantly elevated relative to those who did not report development of heart failure (P<0.0001). Receiver operating characteristic analyses of PNC demonstrate diagnostic value for subclinical heart failure. Additionally, PNC has diagnostic potential when comparing participants with no reported heart failure risk factors from cohort A to at‐risk participants from cohort B over the 13‐year follow‐up. Participants whose PNC levels measure >6 ng/mL have a 41% increased risk of all‐cause mortality independent of age, body mass index, sex, NT‐proBNP, blood pressure, previous heart attack, and coronary artery disease (P=0.044, n=596). CONCLUSIONS: These data suggest that PNC is an early marker of heart failure and has the potential to identify patients who would benefit from early therapeutic intervention. John Wiley and Sons Inc. 2023-03-09 /pmc/articles/PMC10111553/ /pubmed/36892069 http://dx.doi.org/10.1161/JAHA.122.028234 Text en © 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Ferrell, Paul Durham
Oristian, Kristianne Michelle
Puranam, Ishaan
Pizzo, Salvatore Vincent
Serum Pro‐N‐Cadherin Is a Marker of Subclinical Heart Failure in the General Population
title Serum Pro‐N‐Cadherin Is a Marker of Subclinical Heart Failure in the General Population
title_full Serum Pro‐N‐Cadherin Is a Marker of Subclinical Heart Failure in the General Population
title_fullStr Serum Pro‐N‐Cadherin Is a Marker of Subclinical Heart Failure in the General Population
title_full_unstemmed Serum Pro‐N‐Cadherin Is a Marker of Subclinical Heart Failure in the General Population
title_short Serum Pro‐N‐Cadherin Is a Marker of Subclinical Heart Failure in the General Population
title_sort serum pro‐n‐cadherin is a marker of subclinical heart failure in the general population
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111553/
https://www.ncbi.nlm.nih.gov/pubmed/36892069
http://dx.doi.org/10.1161/JAHA.122.028234
work_keys_str_mv AT ferrellpauldurham serumproncadherinisamarkerofsubclinicalheartfailureinthegeneralpopulation
AT oristiankristiannemichelle serumproncadherinisamarkerofsubclinicalheartfailureinthegeneralpopulation
AT puranamishaan serumproncadherinisamarkerofsubclinicalheartfailureinthegeneralpopulation
AT pizzosalvatorevincent serumproncadherinisamarkerofsubclinicalheartfailureinthegeneralpopulation